---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-25-000122"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:45:25.346820+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q2 product revenue $81.5M (+164% YoY); ZORYVE foam approved for scalp/body psoriasis

## Summary
- Net product revenue $81.5M vs $30.9M YoY, driven by ZORYVE portfolio demand across four approved indications.
- Net loss narrowed to $15.9M ($0.13/sh) from $52.3M ($0.42/sh) YoY; cash $191.1M as of June 30.
- ZORYVE foam 0.3% approved in May 2025 for scalp/body psoriasis; sales commenced in June.
- PDUFA date Oct 13, 2025 for ZORYVE cream 0.05% in children 2–5 with atopic dermatitis.
- IND submitted for ARQ-234 (CD200R agonist); halted ARQ-255 (alopecia areata) program.

## SEC filing metadata
- accession: 0001787306-25-000122
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000122/0001787306-25-000122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000122/arqt-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-25-000122
- JSON: https://secwatch.observer/filing/0001787306-25-000122.json
- Plain text: https://secwatch.observer/filing/0001787306-25-000122.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.